<html>
    <head>
        <meta charset="utf-8">
        
            <script src="lib/bindings/utils.js"></script>
            <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/dist/vis-network.min.css" integrity="sha512-WgxfT5LWjfszlPHXRmBWHkV2eceiWTOBvrKCNbdgDYTHrT2AeLCGbF4sZlZw3UMN3WtL0tGUoIAKsu8mllg/XA==" crossorigin="anonymous" referrerpolicy="no-referrer" />
            <script src="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/vis-network.min.js" integrity="sha512-LnvoEWDFrqGHlHmDD2101OrLcbsfkrzoSpvtSQtxK3RMnRV0eOkhhBN2dXHKRrUU8p2DGRTk35n4O8nWSVe1mQ==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>
            
        
<center>
<h1></h1>
</center>

<!-- <link rel="stylesheet" href="../node_modules/vis/dist/vis.min.css" type="text/css" />
<script type="text/javascript" src="../node_modules/vis/dist/vis.js"> </script>-->
        <link
          href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/css/bootstrap.min.css"
          rel="stylesheet"
          integrity="sha384-eOJMYsd53ii+scO/bJGFsiCZc+5NDVN2yr8+0RDqr0Ql0h+rP48ckxlpbzKgwra6"
          crossorigin="anonymous"
        />
        <script
          src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/js/bootstrap.bundle.min.js"
          integrity="sha384-JEW9xMcG8R+pH31jmWH6WWP0WintQrMb4s7ZOdauHnUtxwoG2vI5DkLtS3qm9Ekf"
          crossorigin="anonymous"
        ></script>


        <center>
          <h1></h1>
        </center>
        <style type="text/css">

             #mynetwork {
                 width: 100%;
                 height: 600px;
                 background-color: #ffffff;
                 border: 1px solid lightgray;
                 position: relative;
                 float: left;
             }

             
             #loadingBar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width: 100%;
                 height: 600px;
                 background-color:rgba(200,200,200,0.8);
                 -webkit-transition: all 0.5s ease;
                 -moz-transition: all 0.5s ease;
                 -ms-transition: all 0.5s ease;
                 -o-transition: all 0.5s ease;
                 transition: all 0.5s ease;
                 opacity:1;
             }

             #bar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width:20px;
                 height:20px;
                 margin:auto auto auto auto;
                 border-radius:11px;
                 border:2px solid rgba(30,30,30,0.05);
                 background: rgb(0, 173, 246); /* Old browsers */
                 box-shadow: 2px 0px 4px rgba(0,0,0,0.4);
             }

             #border {
                 position:absolute;
                 top:10px;
                 left:10px;
                 width:500px;
                 height:23px;
                 margin:auto auto auto auto;
                 box-shadow: 0px 0px 4px rgba(0,0,0,0.2);
                 border-radius:10px;
             }

             #text {
                 position:absolute;
                 top:8px;
                 left:530px;
                 width:30px;
                 height:50px;
                 margin:auto auto auto auto;
                 font-size:22px;
                 color: #000000;
             }

             div.outerBorder {
                 position:relative;
                 top:400px;
                 width:600px;
                 height:44px;
                 margin:auto auto auto auto;
                 border:8px solid rgba(0,0,0,0.1);
                 background: rgb(252,252,252); /* Old browsers */
                 background: -moz-linear-gradient(top,  rgba(252,252,252,1) 0%, rgba(237,237,237,1) 100%); /* FF3.6+ */
                 background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,rgba(252,252,252,1)), color-stop(100%,rgba(237,237,237,1))); /* Chrome,Safari4+ */
                 background: -webkit-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Chrome10+,Safari5.1+ */
                 background: -o-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Opera 11.10+ */
                 background: -ms-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* IE10+ */
                 background: linear-gradient(to bottom,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* W3C */
                 filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#fcfcfc', endColorstr='#ededed',GradientType=0 ); /* IE6-9 */
                 border-radius:72px;
                 box-shadow: 0px 0px 10px rgba(0,0,0,0.2);
             }
             

             

             
        </style>
    </head>


    <body>
        <div class="card" style="width: 100%">
            
            
            <div id="mynetwork" class="card-body"></div>
        </div>

        
            <div id="loadingBar">
              <div class="outerBorder">
                <div id="text">0%</div>
                <div id="border">
                  <div id="bar"></div>
                </div>
              </div>
            </div>
        
        

        <script type="text/javascript">

              // initialize global variables.
              var edges;
              var nodes;
              var allNodes;
              var allEdges;
              var nodeColors;
              var originalNodes;
              var network;
              var container;
              var options, data;
              var filter = {
                  item : '',
                  property : '',
                  value : []
              };

              

              

              // This method is responsible for drawing the graph, returns the drawn network
              function drawGraph() {
                  var container = document.getElementById('mynetwork');

                  

                  // parsing and collecting nodes and edges from the python
                  nodes = new vis.DataSet([{"color": "#89CFF0", "id": "Daratumumab", "label": "Daratumumab", "shape": "dot", "title": "DRUG: Daratumumab"}, {"color": "#D3D3D3", "id": "A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator\u0027s C", "label": "A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator\u0027s C", "shape": "dot", "title": "OTHER: A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator\u0027s C"}, {"color": "#B0E57C", "id": "NCT03639948", "label": "NCT03639948", "shape": "dot", "title": "TRIAL: NCT03639948"}, {"color": "#B0E57C", "id": "NCT03098550", "label": "NCT03098550", "shape": "dot", "title": "TRIAL: NCT03098550"}, {"color": "#89CFF0", "id": "Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum", "label": "Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum", "shape": "dot", "title": "DRUG: Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum"}, {"color": "#89CFF0", "id": "Open-Label Study of Bevacizumab (Avastin\u00ae) and Taxane Monotherapy for the First-Line Treatment of Pa", "label": "Open-Label Study of Bevacizumab (Avastin\u00ae) and Taxane Monotherapy for the First-Line Treatment of Pa", "shape": "dot", "title": "DRUG: Open-Label Study of Bevacizumab (Avastin\u00ae) and Taxane Monotherapy for the First-Line Treatment of Pa"}, {"color": "#89CFF0", "id": "A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti", "label": "A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti", "shape": "dot", "title": "DRUG: A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti"}, {"color": "#B0E57C", "id": "NCT04504669", "label": "NCT04504669", "shape": "dot", "title": "TRIAL: NCT04504669"}, {"color": "#89CFF0", "id": "Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection", "label": "Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection", "shape": "dot", "title": "DRUG: Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection"}, {"color": "#89CFF0", "id": "Nivolumab", "label": "Nivolumab", "shape": "dot", "title": "DRUG: Nivolumab"}, {"color": "#B0E57C", "id": "NCT02513472", "label": "NCT02513472", "shape": "dot", "title": "TRIAL: NCT02513472"}, {"color": "#D3D3D3", "id": "ixabepilone + cetuximab", "label": "ixabepilone + cetuximab", "shape": "dot", "title": "OTHER: ixabepilone + cetuximab"}, {"color": "#B0E57C", "id": "NCT04596150", "label": "NCT04596150", "shape": "dot", "title": "TRIAL: NCT04596150"}, {"color": "#89CFF0", "id": "Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr", "label": "Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr", "shape": "dot", "title": "DRUG: Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr"}, {"color": "#B0E57C", "id": "NCT00203502", "label": "NCT00203502", "shape": "dot", "title": "TRIAL: NCT00203502"}, {"color": "#89CFF0", "id": "Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer", "label": "Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer", "shape": "dot", "title": "DRUG: Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer"}, {"color": "#B0E57C", "id": "NCT02644369", "label": "NCT02644369", "shape": "dot", "title": "TRIAL: NCT02644369"}, {"color": "#B0E57C", "id": "NCT02734290", "label": "NCT02734290", "shape": "dot", "title": "TRIAL: NCT02734290"}, {"color": "#89CFF0", "id": "Sacituzumab Govitecan-Hziy", "label": "Sacituzumab Govitecan-Hziy", "shape": "dot", "title": "DRUG: Sacituzumab Govitecan-Hziy"}, {"color": "#89CFF0", "id": "Atezolizumab 840 MG in 14 ML Injection", "label": "Atezolizumab 840 MG in 14 ML Injection", "shape": "dot", "title": "DRUG: Atezolizumab 840 MG in 14 ML Injection"}, {"color": "#89CFF0", "id": "Atezolizumab 1200 MG in 20 ML Injection", "label": "Atezolizumab 1200 MG in 20 ML Injection", "shape": "dot", "title": "DRUG: Atezolizumab 1200 MG in 20 ML Injection"}, {"color": "#89CFF0", "id": "Atezolizumab Placebo", "label": "Atezolizumab Placebo", "shape": "dot", "title": "DRUG: Atezolizumab Placebo"}, {"color": "#D3D3D3", "id": "XmAb\u00ae22841", "label": "XmAb\u00ae22841", "shape": "dot", "title": "OTHER: XmAb\u00ae22841"}, {"color": "#B0E57C", "id": "NCT02447003", "label": "NCT02447003", "shape": "dot", "title": "TRIAL: NCT02447003"}, {"color": "#B0E57C", "id": "NCT03577743", "label": "NCT03577743", "shape": "dot", "title": "TRIAL: NCT03577743"}, {"color": "#B0E57C", "id": "NCT05609903", "label": "NCT05609903", "shape": "dot", "title": "TRIAL: NCT05609903"}, {"color": "#B0E57C", "id": "NCT04770272", "label": "NCT04770272", "shape": "dot", "title": "TRIAL: NCT04770272"}, {"color": "#B0E57C", "id": "NCT02838823", "label": "NCT02838823", "shape": "dot", "title": "TRIAL: NCT02838823"}, {"color": "#89CFF0", "id": "Sacituzumab govitecan", "label": "Sacituzumab govitecan", "shape": "dot", "title": "DRUG: Sacituzumab govitecan"}, {"color": "#89CFF0", "id": "A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae22841 Monotherapy and ", "label": "A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae22841 Monotherapy and ", "shape": "dot", "title": "DRUG: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae22841 Monotherapy and "}, {"color": "#B0E57C", "id": "NCT05520723", "label": "NCT05520723", "shape": "dot", "title": "TRIAL: NCT05520723"}, {"color": "#B0E57C", "id": "NCT03849469", "label": "NCT03849469", "shape": "dot", "title": "TRIAL: NCT03849469"}, {"color": "#B0E57C", "id": "NCT03125902", "label": "NCT03125902", "shape": "dot", "title": "TRIAL: NCT03125902"}, {"color": "#89CFF0", "id": "Bevacizumab", "label": "Bevacizumab", "shape": "dot", "title": "DRUG: Bevacizumab"}, {"color": "#B0E57C", "id": "NCT05374512", "label": "NCT05374512", "shape": "dot", "title": "TRIAL: NCT05374512"}, {"color": "#89CFF0", "id": "Trastuzumab", "label": "Trastuzumab", "shape": "dot", "title": "DRUG: Trastuzumab"}, {"color": "#B0E57C", "id": "NCT03917381", "label": "NCT03917381", "shape": "dot", "title": "TRIAL: NCT03917381"}, {"color": "#B0E57C", "id": "NCT04849364", "label": "NCT04849364", "shape": "dot", "title": "TRIAL: NCT04849364"}, {"color": "#89CFF0", "id": "humanized anti-PD-1 monoclonal antibody toripalimab", "label": "humanized anti-PD-1 monoclonal antibody toripalimab", "shape": "dot", "title": "DRUG: humanized anti-PD-1 monoclonal antibody toripalimab"}, {"color": "#89CFF0", "id": "Trastuzumab deruxtecan", "label": "Trastuzumab deruxtecan", "shape": "dot", "title": "DRUG: Trastuzumab deruxtecan"}, {"color": "#89CFF0", "id": "Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub", "label": "Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub", "shape": "dot", "title": "DRUG: Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub"}, {"color": "#89CFF0", "id": "Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation", "label": "Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation", "shape": "dot", "title": "DRUG: Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation"}, {"color": "#B0E57C", "id": "NCT03801369", "label": "NCT03801369", "shape": "dot", "title": "TRIAL: NCT03801369"}, {"color": "#89CFF0", "id": "A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A", "label": "A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A", "shape": "dot", "title": "DRUG: A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A"}, {"color": "#B0E57C", "id": "NCT05809895", "label": "NCT05809895", "shape": "dot", "title": "TRIAL: NCT05809895"}, {"color": "#D3D3D3", "id": "A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine", "label": "A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine", "shape": "dot", "title": "OTHER: A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine"}, {"color": "#89CFF0", "id": "Pembrolizumab(KEYTRUDA\u00ae)", "label": "Pembrolizumab(KEYTRUDA\u00ae)", "shape": "dot", "title": "DRUG: Pembrolizumab(KEYTRUDA\u00ae)"}, {"color": "#89CFF0", "id": "Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment ", "label": "Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment ", "shape": "dot", "title": "DRUG: Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment "}, {"color": "#89CFF0", "id": "Atezolizumab in combination with nab-paclitaxel", "label": "Atezolizumab in combination with nab-paclitaxel", "shape": "dot", "title": "DRUG: Atezolizumab in combination with nab-paclitaxel"}, {"color": "#B0E57C", "id": "NCT04508803", "label": "NCT04508803", "shape": "dot", "title": "TRIAL: NCT04508803"}, {"color": "#89CFF0", "id": "A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati", "label": "A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati", "shape": "dot", "title": "DRUG: A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati"}, {"color": "#B0E57C", "id": "NCT01094184", "label": "NCT01094184", "shape": "dot", "title": "TRIAL: NCT01094184"}, {"color": "#89CFF0", "id": "cemiplimab", "label": "cemiplimab", "shape": "dot", "title": "DRUG: cemiplimab"}, {"color": "#B0E57C", "id": "NCT04690855", "label": "NCT04690855", "shape": "dot", "title": "TRIAL: NCT04690855"}, {"color": "#89CFF0", "id": "tremelimumab", "label": "tremelimumab", "shape": "dot", "title": "DRUG: tremelimumab"}, {"color": "#89CFF0", "id": "BIOLOGICAL", "label": "BIOLOGICAL", "shape": "dot", "title": "DRUG: BIOLOGICAL"}, {"color": "#89CFF0", "id": "bevacizumab [Avastin]", "label": "bevacizumab [Avastin]", "shape": "dot", "title": "DRUG: bevacizumab [Avastin]"}, {"color": "#89CFF0", "id": "Ipilimumab", "label": "Ipilimumab", "shape": "dot", "title": "DRUG: Ipilimumab"}, {"color": "#B0E57C", "id": "NCT02658214", "label": "NCT02658214", "shape": "dot", "title": "TRIAL: NCT02658214"}, {"color": "#B0E57C", "id": "NCT03752723", "label": "NCT03752723", "shape": "dot", "title": "TRIAL: NCT03752723"}, {"color": "#89CFF0", "id": "HX008\uff0cNiraparib\uff0cTrastuzumab", "label": "HX008\uff0cNiraparib\uff0cTrastuzumab", "shape": "dot", "title": "DRUG: HX008\uff0cNiraparib\uff0cTrastuzumab"}, {"color": "#89CFF0", "id": "A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple", "label": "A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple", "shape": "dot", "title": "DRUG: A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple"}, {"color": "#89CFF0", "id": "A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B", "label": "A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B", "shape": "dot", "title": "DRUG: A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B"}, {"color": "#89CFF0", "id": "Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)", "label": "Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)", "shape": "dot", "title": "DRUG: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)"}, {"color": "#B0E57C", "id": "NCT03414684", "label": "NCT03414684", "shape": "dot", "title": "TRIAL: NCT03414684"}, {"color": "#89CFF0", "id": "Pembrolizumab", "label": "Pembrolizumab", "shape": "dot", "title": "DRUG: Pembrolizumab"}, {"color": "#B0E57C", "id": "NCT01250379", "label": "NCT01250379", "shape": "dot", "title": "TRIAL: NCT01250379"}, {"color": "#B0E57C", "id": "NCT03449108", "label": "NCT03449108", "shape": "dot", "title": "TRIAL: NCT03449108"}, {"color": "#89CFF0", "id": "Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati", "label": "Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati", "shape": "dot", "title": "DRUG: Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati"}, {"color": "#89CFF0", "id": "bevacizumab", "label": "bevacizumab", "shape": "dot", "title": "DRUG: bevacizumab"}, {"color": "#89CFF0", "id": "Ramucirumab DP", "label": "Ramucirumab DP", "shape": "dot", "title": "DRUG: Ramucirumab DP"}, {"color": "#B0E57C", "id": "NCT00691379", "label": "NCT00691379", "shape": "dot", "title": "TRIAL: NCT00691379"}, {"color": "#89CFF0", "id": "DRUG", "label": "DRUG", "shape": "dot", "title": "DRUG: DRUG"}, {"color": "#B0E57C", "id": "NCT02957968", "label": "NCT02957968", "shape": "dot", "title": "TRIAL: NCT02957968"}, {"color": "#B0E57C", "id": "NCT05194072", "label": "NCT05194072", "shape": "dot", "title": "TRIAL: NCT05194072"}, {"color": "#89CFF0", "id": "Durvalumab", "label": "Durvalumab", "shape": "dot", "title": "DRUG: Durvalumab"}, {"color": "#89CFF0", "id": "Oleclumab", "label": "Oleclumab", "shape": "dot", "title": "DRUG: Oleclumab"}, {"color": "#89CFF0", "id": "Ociperlimab", "label": "Ociperlimab", "shape": "dot", "title": "DRUG: Ociperlimab"}, {"color": "#B0E57C", "id": "NCT01969643", "label": "NCT01969643", "shape": "dot", "title": "TRIAL: NCT01969643"}, {"color": "#B0E57C", "id": "NCT00733408", "label": "NCT00733408", "shape": "dot", "title": "TRIAL: NCT00733408"}, {"color": "#89CFF0", "id": "Tislelizumab", "label": "Tislelizumab", "shape": "dot", "title": "DRUG: Tislelizumab"}, {"color": "#B0E57C", "id": "NCT04177108", "label": "NCT04177108", "shape": "dot", "title": "TRIAL: NCT04177108"}, {"color": "#D3D3D3", "id": "Datopotamab deruxtecan", "label": "Datopotamab deruxtecan", "shape": "dot", "title": "OTHER: Datopotamab deruxtecan"}, {"color": "#FFD700", "id": "Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan\u0027s Tole", "label": "Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan\u0027s Tole", "shape": "dot", "title": "SPONSOR: Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan\u0027s Tole"}, {"color": "#89CFF0", "id": "Acasunlimab", "label": "Acasunlimab", "shape": "dot", "title": "DRUG: Acasunlimab"}, {"color": "#B0E57C", "id": "NCT03775850", "label": "NCT03775850", "shape": "dot", "title": "TRIAL: NCT03775850"}, {"color": "#89CFF0", "id": "Tiragolumab", "label": "Tiragolumab", "shape": "dot", "title": "DRUG: Tiragolumab"}, {"color": "#B0E57C", "id": "NCT02755272", "label": "NCT02755272", "shape": "dot", "title": "TRIAL: NCT02755272"}, {"color": "#89CFF0", "id": "ladiratuzumab vedotin", "label": "ladiratuzumab vedotin", "shape": "dot", "title": "DRUG: ladiratuzumab vedotin"}, {"color": "#89CFF0", "id": "A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab", "label": "A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab", "shape": "dot", "title": "DRUG: A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab"}, {"color": "#FFD700", "id": "A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P", "label": "A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P", "shape": "dot", "title": "SPONSOR: A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P"}, {"color": "#B0E57C", "id": "NCT04927884", "label": "NCT04927884", "shape": "dot", "title": "TRIAL: NCT04927884"}, {"color": "#B0E57C", "id": "NCT03742102", "label": "NCT03742102", "shape": "dot", "title": "TRIAL: NCT03742102"}, {"color": "#89CFF0", "id": "A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in", "label": "A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in", "shape": "dot", "title": "DRUG: A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in"}, {"color": "#89CFF0", "id": "Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast", "label": "Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast", "shape": "dot", "title": "DRUG: Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast"}, {"color": "#B0E57C", "id": "NCT04521621", "label": "NCT04521621", "shape": "dot", "title": "TRIAL: NCT04521621"}, {"color": "#D3D3D3", "id": "Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen", "label": "Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen", "shape": "dot", "title": "OTHER: Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen"}, {"color": "#B0E57C", "id": "NCT00633464", "label": "NCT00633464", "shape": "dot", "title": "TRIAL: NCT00633464"}, {"color": "#B0E57C", "id": "NCT04916002", "label": "NCT04916002", "shape": "dot", "title": "TRIAL: NCT04916002"}, {"color": "#B0E57C", "id": "NCT04514484", "label": "NCT04514484", "shape": "dot", "title": "TRIAL: NCT04514484"}, {"color": "#B0E57C", "id": "NCT01234402", "label": "NCT01234402", "shape": "dot", "title": "TRIAL: NCT01234402"}, {"color": "#89CFF0", "id": "A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che", "label": "A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che", "shape": "dot", "title": "DRUG: A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che"}, {"color": "#89CFF0", "id": "Atezolizumab", "label": "Atezolizumab", "shape": "dot", "title": "DRUG: Atezolizumab"}, {"color": "#89CFF0", "id": "Placebo for Atezolizumab", "label": "Placebo for Atezolizumab", "shape": "dot", "title": "DRUG: Placebo for Atezolizumab"}, {"color": "#89CFF0", "id": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "label": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "shape": "dot", "title": "DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"}, {"color": "#D3D3D3", "id": "Genmab", "label": "Genmab", "shape": "dot", "title": "OTHER: Genmab"}, {"color": "#89CFF0", "id": "Pembrolizumab (Keytruda\u00ae)", "label": "Pembrolizumab (Keytruda\u00ae)", "shape": "dot", "title": "DRUG: Pembrolizumab (Keytruda\u00ae)"}, {"color": "#89CFF0", "id": "Acasunlimab in combination with docetaxel (in a single expansion cohort)", "label": "Acasunlimab in combination with docetaxel (in a single expansion cohort)", "shape": "dot", "title": "DRUG: Acasunlimab in combination with docetaxel (in a single expansion cohort)"}, {"color": "#B0E57C", "id": "NCT04584112", "label": "NCT04584112", "shape": "dot", "title": "TRIAL: NCT04584112"}, {"color": "#B0E57C", "id": "NCT04925284", "label": "NCT04925284", "shape": "dot", "title": "TRIAL: NCT04925284"}, {"color": "#89CFF0", "id": "durvalumab", "label": "durvalumab", "shape": "dot", "title": "DRUG: durvalumab"}]);
                  edges = new vis.DataSet([{"arrows": "to", "from": "NCT03639948", "label": "has_title", "title": "NCT03639948 \u2192 Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast", "to": "Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast"}, {"arrows": "to", "from": "NCT03639948", "label": "tests", "title": "NCT03639948 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03414684", "label": "has_title", "title": "NCT03414684 \u2192 A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple", "to": "A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple"}, {"arrows": "to", "from": "NCT03414684", "label": "tests", "title": "NCT03414684 \u2192 Nivolumab", "to": "Nivolumab"}, {"arrows": "to", "from": "Nivolumab", "label": "has_type", "title": "Nivolumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT01094184", "label": "has_title", "title": "NCT01094184 \u2192 Open-Label Study of Bevacizumab (Avastin\u00ae) and Taxane Monotherapy for the First-Line Treatment of Pa", "to": "Open-Label Study of Bevacizumab (Avastin\u00ae) and Taxane Monotherapy for the First-Line Treatment of Pa"}, {"arrows": "to", "from": "NCT01094184", "label": "tests", "title": "NCT01094184 \u2192 Bevacizumab", "to": "Bevacizumab"}, {"arrows": "to", "from": "Bevacizumab", "label": "has_type", "title": "Bevacizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04514484", "label": "has_title", "title": "NCT04514484 \u2192 Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection", "to": "Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection"}, {"arrows": "to", "from": "NCT04514484", "label": "tests", "title": "NCT04514484 \u2192 Nivolumab", "to": "Nivolumab"}, {"arrows": "to", "from": "Nivolumab", "label": "has_type", "title": "Nivolumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03125902", "label": "has_title", "title": "NCT03125902 \u2192 A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P", "to": "A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P"}, {"arrows": "to", "from": "NCT03125902", "label": "tests", "title": "NCT03125902 \u2192 Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "to": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"}, {"arrows": "to", "from": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody", "label": "has_type", "title": "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03125902", "label": "tests", "title": "NCT03125902 \u2192 Atezolizumab Placebo", "to": "Atezolizumab Placebo"}, {"arrows": "to", "from": "Atezolizumab Placebo", "label": "has_type", "title": "Atezolizumab Placebo \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03742102", "label": "tests", "title": "NCT03742102 \u2192 Durvalumab", "to": "Durvalumab"}, {"arrows": "to", "from": "Durvalumab", "label": "has_type", "title": "Durvalumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03742102", "label": "tests", "title": "NCT03742102 \u2192 Oleclumab", "to": "Oleclumab"}, {"arrows": "to", "from": "Oleclumab", "label": "has_type", "title": "Oleclumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03742102", "label": "tests", "title": "NCT03742102 \u2192 Trastuzumab deruxtecan", "to": "Trastuzumab deruxtecan"}, {"arrows": "to", "from": "Trastuzumab deruxtecan", "label": "has_type", "title": "Trastuzumab deruxtecan \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03742102", "label": "tests", "title": "NCT03742102 \u2192 Datopotamab deruxtecan", "to": "Datopotamab deruxtecan"}, {"arrows": "to", "from": "Datopotamab deruxtecan", "label": "has_type", "title": "Datopotamab deruxtecan \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT01234402", "label": "tests", "title": "NCT01234402 \u2192 Ramucirumab DP", "to": "Ramucirumab DP"}, {"arrows": "to", "from": "Ramucirumab DP", "label": "has_type", "title": "Ramucirumab DP \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT04521621", "label": "has_title", "title": "NCT04521621 \u2192 A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab", "to": "A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab"}, {"arrows": "to", "from": "NCT04521621", "label": "tests", "title": "NCT04521621 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04849364", "label": "tests", "title": "NCT04849364 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT00203502", "label": "has_title", "title": "NCT00203502 \u2192 Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub", "to": "Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub"}, {"arrows": "to", "from": "NCT00203502", "label": "tests", "title": "NCT00203502 \u2192 Bevacizumab", "to": "Bevacizumab"}, {"arrows": "to", "from": "Bevacizumab", "label": "has_type", "title": "Bevacizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04916002", "label": "tests", "title": "NCT04916002 \u2192 cemiplimab", "to": "cemiplimab"}, {"arrows": "to", "from": "cemiplimab", "label": "has_type", "title": "cemiplimab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04925284", "label": "tests", "title": "NCT04925284 \u2192 Nivolumab", "to": "Nivolumab"}, {"arrows": "to", "from": "Nivolumab", "label": "has_type", "title": "Nivolumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04925284", "label": "tests", "title": "NCT04925284 \u2192 Bevacizumab", "to": "Bevacizumab"}, {"arrows": "to", "from": "Bevacizumab", "label": "has_type", "title": "Bevacizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04927884", "label": "has_title", "title": "NCT04927884 \u2192 Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment ", "to": "Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment "}, {"arrows": "to", "from": "NCT04927884", "label": "tests", "title": "NCT04927884 \u2192 Sacituzumab Govitecan-Hziy", "to": "Sacituzumab Govitecan-Hziy"}, {"arrows": "to", "from": "Sacituzumab Govitecan-Hziy", "label": "has_type", "title": "Sacituzumab Govitecan-Hziy \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT01250379", "label": "tests", "title": "NCT01250379 \u2192 bevacizumab [Avastin]", "to": "bevacizumab [Avastin]"}, {"arrows": "to", "from": "bevacizumab [Avastin]", "label": "has_type", "title": "bevacizumab [Avastin] \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT00691379", "label": "has_title", "title": "NCT00691379 \u2192 Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati", "to": "Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati"}, {"arrows": "to", "from": "NCT00691379", "label": "tests", "title": "NCT00691379 \u2192 Bevacizumab", "to": "Bevacizumab"}, {"arrows": "to", "from": "Bevacizumab", "label": "has_type", "title": "Bevacizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT00633464", "label": "has_title", "title": "NCT00633464 \u2192 Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen", "to": "Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen"}, {"arrows": "to", "from": "NCT00633464", "label": "tests", "title": "NCT00633464 \u2192 ixabepilone + cetuximab", "to": "ixabepilone + cetuximab"}, {"arrows": "to", "from": "ixabepilone + cetuximab", "label": "has_type", "title": "ixabepilone + cetuximab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03449108", "label": "tests", "title": "NCT03449108 \u2192 Ipilimumab", "to": "Ipilimumab"}, {"arrows": "to", "from": "Ipilimumab", "label": "has_type", "title": "Ipilimumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03449108", "label": "tests", "title": "NCT03449108 \u2192 Nivolumab", "to": "Nivolumab"}, {"arrows": "to", "from": "Nivolumab", "label": "has_type", "title": "Nivolumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT00733408", "label": "tests", "title": "NCT00733408 \u2192 bevacizumab", "to": "bevacizumab"}, {"arrows": "to", "from": "bevacizumab", "label": "has_type", "title": "bevacizumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT04596150", "label": "has_title", "title": "NCT04596150 \u2192 A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine", "to": "A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine"}, {"arrows": "to", "from": "NCT05809895", "label": "tests", "title": "NCT05809895 \u2192 Ociperlimab", "to": "Ociperlimab"}, {"arrows": "to", "from": "Ociperlimab", "label": "has_type", "title": "Ociperlimab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT05809895", "label": "tests", "title": "NCT05809895 \u2192 Tislelizumab", "to": "Tislelizumab"}, {"arrows": "to", "from": "Tislelizumab", "label": "has_type", "title": "Tislelizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT05809895", "label": "tests", "title": "NCT05809895 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04690855", "label": "tests", "title": "NCT04690855 \u2192 Atezolizumab", "to": "Atezolizumab"}, {"arrows": "to", "from": "Atezolizumab", "label": "has_type", "title": "Atezolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03098550", "label": "has_title", "title": "NCT03098550 \u2192 Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum", "to": "Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum"}, {"arrows": "to", "from": "NCT03098550", "label": "tests", "title": "NCT03098550 \u2192 Nivolumab", "to": "Nivolumab"}, {"arrows": "to", "from": "Nivolumab", "label": "has_type", "title": "Nivolumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03098550", "label": "tests", "title": "NCT03098550 \u2192 Daratumumab", "to": "Daratumumab"}, {"arrows": "to", "from": "Daratumumab", "label": "has_type", "title": "Daratumumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03775850", "label": "has_title", "title": "NCT03775850 \u2192 A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A", "to": "A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A"}, {"arrows": "to", "from": "NCT03775850", "label": "tests", "title": "NCT03775850 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT02838823", "label": "tests", "title": "NCT02838823 \u2192 humanized anti-PD-1 monoclonal antibody toripalimab", "to": "humanized anti-PD-1 monoclonal antibody toripalimab"}, {"arrows": "to", "from": "humanized anti-PD-1 monoclonal antibody toripalimab", "label": "has_type", "title": "humanized anti-PD-1 monoclonal antibody toripalimab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT04177108", "label": "tests", "title": "NCT04177108 \u2192 Atezolizumab", "to": "Atezolizumab"}, {"arrows": "to", "from": "Atezolizumab", "label": "has_type", "title": "Atezolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04177108", "label": "tests", "title": "NCT04177108 \u2192 Placebo for Atezolizumab", "to": "Placebo for Atezolizumab"}, {"arrows": "to", "from": "Placebo for Atezolizumab", "label": "has_type", "title": "Placebo for Atezolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03752723", "label": "tests", "title": "NCT03752723 \u2192 Pembrolizumab(KEYTRUDA\u00ae)", "to": "Pembrolizumab(KEYTRUDA\u00ae)"}, {"arrows": "to", "from": "Pembrolizumab(KEYTRUDA\u00ae)", "label": "has_type", "title": "Pembrolizumab(KEYTRUDA\u00ae) \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT02658214", "label": "has_title", "title": "NCT02658214 \u2192 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati", "to": "A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati"}, {"arrows": "to", "from": "NCT02658214", "label": "tests", "title": "NCT02658214 \u2192 durvalumab", "to": "durvalumab"}, {"arrows": "to", "from": "durvalumab", "label": "has_type", "title": "durvalumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT02658214", "label": "tests", "title": "NCT02658214 \u2192 tremelimumab", "to": "tremelimumab"}, {"arrows": "to", "from": "tremelimumab", "label": "has_type", "title": "tremelimumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT05520723", "label": "has_title", "title": "NCT05520723 \u2192 Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan\u0027s Tole", "to": "Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan\u0027s Tole"}, {"arrows": "to", "from": "NCT05520723", "label": "tests", "title": "NCT05520723 \u2192 Sacituzumab govitecan", "to": "Sacituzumab govitecan"}, {"arrows": "to", "from": "Sacituzumab govitecan", "label": "has_type", "title": "Sacituzumab govitecan \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04508803", "label": "tests", "title": "NCT04508803 \u2192 HX008\uff0cNiraparib\uff0cTrastuzumab", "to": "HX008\uff0cNiraparib\uff0cTrastuzumab"}, {"arrows": "to", "from": "HX008\uff0cNiraparib\uff0cTrastuzumab", "label": "has_type", "title": "HX008\uff0cNiraparib\uff0cTrastuzumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT02734290", "label": "has_title", "title": "NCT02734290 \u2192 A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che", "to": "A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che"}, {"arrows": "to", "from": "NCT02734290", "label": "tests", "title": "NCT02734290 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT05609903", "label": "has_title", "title": "NCT05609903 \u2192 Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr", "to": "Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr"}, {"arrows": "to", "from": "NCT05609903", "label": "tests", "title": "NCT05609903 \u2192 Atezolizumab in combination with nab-paclitaxel", "to": "Atezolizumab in combination with nab-paclitaxel"}, {"arrows": "to", "from": "Atezolizumab in combination with nab-paclitaxel", "label": "has_type", "title": "Atezolizumab in combination with nab-paclitaxel \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03577743", "label": "has_title", "title": "NCT03577743 \u2192 Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer", "to": "Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer"}, {"arrows": "to", "from": "NCT03577743", "label": "tests", "title": "NCT03577743 \u2192 Bevacizumab", "to": "Bevacizumab"}, {"arrows": "to", "from": "Bevacizumab", "label": "has_type", "title": "Bevacizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT01969643", "label": "tests", "title": "NCT01969643 \u2192 ladiratuzumab vedotin", "to": "ladiratuzumab vedotin"}, {"arrows": "to", "from": "ladiratuzumab vedotin", "label": "has_type", "title": "ladiratuzumab vedotin \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT01969643", "label": "tests", "title": "NCT01969643 \u2192 Trastuzumab", "to": "Trastuzumab"}, {"arrows": "to", "from": "Trastuzumab", "label": "has_type", "title": "Trastuzumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04584112", "label": "tests", "title": "NCT04584112 \u2192 Tiragolumab", "to": "Tiragolumab"}, {"arrows": "to", "from": "Tiragolumab", "label": "has_type", "title": "Tiragolumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04584112", "label": "tests", "title": "NCT04584112 \u2192 Atezolizumab", "to": "Atezolizumab"}, {"arrows": "to", "from": "Atezolizumab", "label": "has_type", "title": "Atezolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04584112", "label": "tests", "title": "NCT04584112 \u2192 Tiragolumab", "to": "Tiragolumab"}, {"arrows": "to", "from": "Tiragolumab", "label": "has_type", "title": "Tiragolumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04584112", "label": "tests", "title": "NCT04584112 \u2192 Atezolizumab", "to": "Atezolizumab"}, {"arrows": "to", "from": "Atezolizumab", "label": "has_type", "title": "Atezolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT05374512", "label": "has_title", "title": "NCT05374512 \u2192 A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator\u0027s C", "to": "A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator\u0027s C"}, {"arrows": "to", "from": "NCT02447003", "label": "has_title", "title": "NCT02447003 \u2192 A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B", "to": "A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B"}, {"arrows": "to", "from": "NCT02447003", "label": "tests", "title": "NCT02447003 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03801369", "label": "has_title", "title": "NCT03801369 \u2192 A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti", "to": "A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti"}, {"arrows": "to", "from": "NCT03801369", "label": "tests", "title": "NCT03801369 \u2192 Durvalumab", "to": "Durvalumab"}, {"arrows": "to", "from": "Durvalumab", "label": "has_type", "title": "Durvalumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT02957968", "label": "tests", "title": "NCT02957968 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03849469", "label": "has_title", "title": "NCT03849469 \u2192 A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae22841 Monotherapy and ", "to": "A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae22841 Monotherapy and "}, {"arrows": "to", "from": "NCT03849469", "label": "tests", "title": "NCT03849469 \u2192 XmAb\u00ae22841", "to": "XmAb\u00ae22841"}, {"arrows": "to", "from": "XmAb\u00ae22841", "label": "has_type", "title": "XmAb\u00ae22841 \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03849469", "label": "tests", "title": "NCT03849469 \u2192 Pembrolizumab (Keytruda\u00ae)", "to": "Pembrolizumab (Keytruda\u00ae)"}, {"arrows": "to", "from": "Pembrolizumab (Keytruda\u00ae)", "label": "has_type", "title": "Pembrolizumab (Keytruda\u00ae) \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT02644369", "label": "has_title", "title": "NCT02644369 \u2192 Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation", "to": "Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation"}, {"arrows": "to", "from": "NCT02644369", "label": "tests", "title": "NCT02644369 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT04504669", "label": "tests", "title": "NCT04504669 \u2192 Durvalumab", "to": "Durvalumab"}, {"arrows": "to", "from": "Durvalumab", "label": "has_type", "title": "Durvalumab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT02513472", "label": "tests", "title": "NCT02513472 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT02755272", "label": "has_title", "title": "NCT02755272 \u2192 A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in", "to": "A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in"}, {"arrows": "to", "from": "NCT02755272", "label": "tests", "title": "NCT02755272 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04770272", "label": "tests", "title": "NCT04770272 \u2192 Atezolizumab 840 MG in 14 ML Injection", "to": "Atezolizumab 840 MG in 14 ML Injection"}, {"arrows": "to", "from": "Atezolizumab 840 MG in 14 ML Injection", "label": "has_type", "title": "Atezolizumab 840 MG in 14 ML Injection \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT04770272", "label": "tests", "title": "NCT04770272 \u2192 Atezolizumab 1200 MG in 20 ML Injection", "to": "Atezolizumab 1200 MG in 20 ML Injection"}, {"arrows": "to", "from": "Atezolizumab 1200 MG in 20 ML Injection", "label": "has_type", "title": "Atezolizumab 1200 MG in 20 ML Injection \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT05194072", "label": "tests", "title": "NCT05194072 \u2192 Pembrolizumab", "to": "Pembrolizumab"}, {"arrows": "to", "from": "Pembrolizumab", "label": "has_type", "title": "Pembrolizumab \u2192 DRUG", "to": "DRUG"}, {"arrows": "to", "from": "NCT03917381", "label": "sponsored_by", "title": "NCT03917381 \u2192 Genmab", "to": "Genmab"}, {"arrows": "to", "from": "NCT03917381", "label": "tests", "title": "NCT03917381 \u2192 Acasunlimab", "to": "Acasunlimab"}, {"arrows": "to", "from": "Acasunlimab", "label": "has_type", "title": "Acasunlimab \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03917381", "label": "tests", "title": "NCT03917381 \u2192 Acasunlimab in combination with docetaxel (in a single expansion cohort)", "to": "Acasunlimab in combination with docetaxel (in a single expansion cohort)"}, {"arrows": "to", "from": "Acasunlimab in combination with docetaxel (in a single expansion cohort)", "label": "has_type", "title": "Acasunlimab in combination with docetaxel (in a single expansion cohort) \u2192 BIOLOGICAL", "to": "BIOLOGICAL"}, {"arrows": "to", "from": "NCT03917381", "label": "tests", "title": "NCT03917381 \u2192 Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)", "to": "Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)"}]);

                  nodeColors = {};
                  allNodes = nodes.get({ returnType: "Object" });
                  for (nodeId in allNodes) {
                    nodeColors[nodeId] = allNodes[nodeId].color;
                  }
                  allEdges = edges.get({ returnType: "Object" });
                  // adding nodes and edges to the graph
                  data = {nodes: nodes, edges: edges};

                  var options = {
    "configure": {
        "enabled": false
    },
    "edges": {
        "color": {
            "inherit": true
        },
        "smooth": {
            "enabled": true,
            "type": "dynamic"
        }
    },
    "interaction": {
        "dragNodes": true,
        "hideEdgesOnDrag": false,
        "hideNodesOnDrag": false
    },
    "physics": {
        "enabled": true,
        "stabilization": {
            "enabled": true,
            "fit": true,
            "iterations": 1000,
            "onlyDynamicEdges": false,
            "updateInterval": 50
        }
    }
};

                  


                  

                  network = new vis.Network(container, data, options);

                  

                  

                  


                  
                      network.on("stabilizationProgress", function(params) {
                          document.getElementById('loadingBar').removeAttribute("style");
                          var maxWidth = 496;
                          var minWidth = 20;
                          var widthFactor = params.iterations/params.total;
                          var width = Math.max(minWidth,maxWidth * widthFactor);
                          document.getElementById('bar').style.width = width + 'px';
                          document.getElementById('text').innerHTML = Math.round(widthFactor*100) + '%';
                      });
                      network.once("stabilizationIterationsDone", function() {
                          document.getElementById('text').innerHTML = '100%';
                          document.getElementById('bar').style.width = '496px';
                          document.getElementById('loadingBar').style.opacity = 0;
                          // really clean the dom element
                          setTimeout(function () {document.getElementById('loadingBar').style.display = 'none';}, 500);
                      });
                  

                  return network;

              }
              drawGraph();
        </script>
    </body>
</html>